James Sinclair

Dr James Sinclair is a Senior Research Fellow at the School of Natural and Computing Sciences, University of Aberdeen, with a primary affiliation in the Department of Chemistry. His research bridges synthetic organic chemistry and medicinal applications, particularly in the context of neurodegenerative diseases.

His research interests focus on medicinal chemistry, tau protein aggregation inhibition, and the synthesis of phenothiazinium compounds such as methylthioninium chloride (MTC) for the treatment of Alzheimer's disease and related tauopathies. He has also contributed to supramolecular chemistry and coordination networks, demonstrating expertise in both biological and inorganic systems.

The trend in his publications from 2004 to 2015 shows a strong emphasis on developing therapeutic agents for neurodegeneration, supported by robust synthetic methodologies. His work combines organic synthesis, patent-driven innovation, and biochemical validation, particularly in the context of Alzheimer's disease therapeutics. Several of his articles are patents, highlighting translational research impact.

Dr Sinclair has collaborated extensively with key researchers such as J. M. D. Storey, C. Wischik, and M. Plater, contributing to both journal publications and patented inventions. While no formal advising or grant details are mentioned, his consistent publication record indicates active engagement in funded research projects, likely associated with neurodegeneration and drug development initiatives.

He is part of research groups involved in theoretical and computational chemistry and the SyMBioSIS Group, suggesting interdisciplinary collaboration within the School. His work on nanostructures and coordination networks further indicates involvement in advanced materials research.